[EN] SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS [FR] INDOLES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU VIRUS DE L'HEPATITE C (VHC)
[EN] SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS [FR] INDOLES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU VIRUS DE L'HEPATITE C (VHC)
Novel monomers containing an oxepan-2-one group, photoresist compositions comprising polymers prepared from the monomers, methods for preparing the compositions, and methods for forming photoresist patterns using the compositions
申请人:Kim Jin-Baek
公开号:US20050042539A1
公开(公告)日:2005-02-24
Disclosed herein is a novel norbornene, acrylate or methacrylate monomer as a photoresist monomer containing an oxepan-2-one group. Further disclosed are photoresist compositions comprising a polymer prepared from the monomer, methods for preparing the photoresist compositions, and methods for forming photoresist patterns using the photoresist compositions.
Substituted indoles and their use as hcv inhibitors
申请人:Singh Rajinder
公开号:US20050215614A1
公开(公告)日:2005-09-29
The present invention comprises indole-derivatives that are inhibitors of HCV. Composition comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a mammal.
SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS
申请人:Rigel Pharmaceuticals, Inc.
公开号:EP1554271A1
公开(公告)日:2005-07-20
US6936402B2
申请人:——
公开号:US6936402B2
公开(公告)日:2005-08-30
[EN] SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS<br/>[FR] INDOLES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU VIRUS DE L'HEPATITE C (VHC)
申请人:RIGEL PHARMACEUTICALS INC
公开号:WO2004035571A1
公开(公告)日:2004-04-29
The present invention comprises indole-derivatives that are inhibitors of HCV. Composition comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a mammal.